Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects.

Background: Analytical data suggesting that immunoglobulin given intramuscularly (IGIM) may have reduced protection against hepatitis A virus (HAV) infection led to an update in the recommended IGIM dose (0.2 ml/kg).Methods: This prospective, open-label, single-arm clinical study evaluated whether a...

Descripción completa

Detalles Bibliográficos

Publicado en:	Advances in Therapy Vol. 37; no. 5; pp. 2373 - 2390
Autores principales:	Kankam, Martin, Griffin, Rhonda, Price, Jeffrey, Michaud, Josée, Liang, Wei, Llorens, Mariona Bassas, Sanz, Ana, Vince, Bradley, Vilardell, David
Formato:	clinical trial research tables/charts Journal Article
Publicado:	Springer Nature May2020
Acceso en línea:	Ver este registro en EBSCOhost